MedTrace Logo

SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

NCT07125950 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-15

No results posted yet for this study

Summary

Our study is aimed to evaluate the safety and preliminary of all-oral regimen SHR2554 combined with HRS-8080 or HRS-1358 in advanced breast cancer.

Conditions

Interventions

DRUG

SHR2554

SHR2554

DRUG

HRS-8080

HRS-8080

DRUG

HRS-1358

HRS-1358

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Min Yan, Chief physician · Henan Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-09-30
Completion
2028-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07125950 on ClinicalTrials.gov